RT Journal Article
SR Electronic
T1 Aging and Alzheimer’s Disease Have Dissociable Effects on Medial Temporal Lobe Connectivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.18.23284749
DO 10.1101/2023.01.18.23284749
A1 Hrybouski, Stanislau
A1 Das, Sandhitsu R.
A1 Xie, Long
A1 Wisse, Laura E. M.
A1 Kelley, Melissa
A1 Lane, Jacqueline
A1 Sherin, Monica
A1 DiCalogero, Michael
A1 Nasrallah, Ilya
A1 Detre, John A.
A1 Yushkevich, Paul A.
A1 Wolk, David A.
YR 2023
UL http://medrxiv.org/content/early/2023/01/19/2023.01.18.23284749.abstract
AB Functional disruption of the medial temporal lobe-dependent networks is thought to underlie episodic memory deficits in aging and Alzheimer’s disease. Previous studies revealed that the anterior medial temporal lobe is more vulnerable to pathological and neurodegenerative processes in Alzheimer’s disease. In contrast, cognitive and structural imaging literature indicates posterior, as opposed to anterior, medial temporal lobe vulnerability in normal aging. However, the extent to which Alzheimer’s and aging-related pathological processes relate to functional disruption of the medial temporal lobe-dependent brain networks is poorly understood. To address this knowledge gap, we examined functional connectivity alterations in the medial temporal lobe and its immediate functional neighborhood – the Anterior-Temporal and Posterior-Medial brain networks – in normal agers, individuals with preclinical Alzheimer’s disease, and patients with Mild Cognitive Impairment or mild dementia due to Alzheimer’s disease. In the Anterior-Temporal network and in the perirhinal cortex, in particular, we observed an inverted ‘U-shaped’ relationship between functional connectivity and Alzheimer’s stage. According to our results, the preclinical phase of Alzheimer’s disease is characterized by increased functional connectivity between the perirhinal cortex and other regions of the medial temporal lobe, as well as between the anterior medial temporal lobe and its one-hop neighbors in the Anterior-Temporal system. This effect is no longer present in symptomatic Alzheimer’s disease. Instead, patients with symptomatic Alzheimer’s disease displayed reduced hippocampal connectivity within the medial temporal lobe as well as hypoconnectivity within the Posterior-Medial system. For normal aging, our results led to three main conclusions: (1) intra-network connectivity of both the Anterior-Temporal and Posterior-Medial networks declines with age; (2) the anterior and posterior segments of the medial temporal lobe become increasingly decoupled from each other with advancing age; and, (3) the posterior subregions of the medial temporal lobe, especially the parahippocampal cortex, are more vulnerable to age-associated loss of function than their anterior counterparts. Together, the current results highlight evolving medial temporal lobe dysfunction in Alzheimer’s disease and indicate different neurobiological mechanisms of the medial temporal lobe network disruption in aging vs. Alzheimer’s disease.Competing Interest StatementD.A.W. has served as a paid consultant to Eli Lilly, GE Healthcare, and Qynapse. He serves on a DSMB for Functional Neuromodulation. He receives research support paid to his institution from Biogen. I.N. serves on the Scientific Advisory Board for Eisai and does educational speaking for Biogen. All other authors report no competing interests.Funding StatementThe work in the present study was supported by the Alzheimer's Association Grant AARF-21-848972 and by the National Institutes of Health Grants P30-AG072979, RF1-AG069474, R01-AG056014, R01-AG055005, R01-AG072796 and R01-AG070592.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Pennsylvania Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized preprocessed data and in-house analysis scripts will be made available upon request for the sole purpose of replicating procedures and results presented in this article.ADAlzheimer’s diseaseATanterior-temporalBOLDblood oxygen level-dependentCIcognitively impairedCUcognitively unimpairedERCentorhinal cortexFCfunctional connectivityfMRIfunctionalMRI; HPhippocampusMTLmedial temporal lobePMposterior-medialPHCparahippocampal cortexPRCperirhinal cortex